Genzyme Pharmaceuticals and Brookwood Pharmaceuticals Enter Broad Collaboration in Drug Delivery With an Initial Focus on Peptide Delivery

May 02, 2006, 01:00 ET from Brookwood Pharmaceuticals

    CAMBRIDGE, Mass. and BIRMINGHAM, Ala., May 2 /PRNewswire/ -- Genzyme
 Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood
 Pharmaceuticals, Inc., today announced a broad collaboration to develop
 novel drug delivery solutions, with an initial focus on peptide delivery.
 The partnership offers customized solutions for parenteral formulations by
 combining expertise in design for peptide delivery, peptide synthesis, and
 drug delivery technologies.
     The 'Design for Peptide Delivery' approach optimizes peptide physical
 and chemical properties early on in drug development, so as to match a
 peptide with the properties of microparticles, implants and other drug
 delivery formulations required for optimal drug delivery. Combining the
 capabilities and knowledge of Genzyme and Brookwood in parallel design of
 peptide and delivery systems will result in clients developing
 sophisticated pharmaceutical products that will benefit the patient.
     "Brookwood Pharmaceuticals' scientific team has industry-leading
 experience in a wide range of drug delivery systems, with particular depth
 in long-acting parenterals such as microparticles and solid implants," said
 Dan Hayden, Senior Vice President and General Manager of Genzyme
 Pharmaceuticals. "Combining Brookwood's strengths with Genzyme's expertise
 in custom GMP peptide development and manufacturing provides a powerful
 service to peptide drug delivery customers." In the longer term many new
 and important drug delivery technologies can be developed from the
 portfolio of novel materials and technologies owned by Genzyme and
     "By working with an industry leader like Genzyme, we envision this
 collaboration to generate plenty of energy, creativity, and new drug
 delivery solutions and products, from which our clients will greatly
 benefit," said Arthur Tipton, Ph.D., president and CEO of Brookwood
 Pharmaceuticals. "From our experience in peptide delivery, we have learned
 that focus on peptide modification and peptide properties can greatly aid
 in the stability and performance of a peptide drug delivery product."
     Rather than promoting a specific technology, the Genzyme-Brookwood
 collaboration will offer customers a solution-oriented approach through
 synergistic capabilities and technologies, depending on the peptide and the
 customer's target drug profile. Customers will also benefit from enhanced
 capabilities and services such as research-scale peptide synthesis for
 backbone and side chain modifications, evaluation of available drug
 delivery technologies, large-scale peptide drug substance production,
 formulation feasibility studies and development of micro-encapsulation
 processes, drug excipients manufacturing (phospholipids and polymers), drug
 product formulation, and manufacturing of clinical supplies and final drug
 delivery product.
     About Brookwood Pharmaceuticals
     Brookwood Pharmaceuticals, a for-profit subsidiary of Southern Research
 Institute, is a drug delivery company based in Birmingham, Alabama with
 formulation and scale up laboratories, clean rooms and a quality system
 that supports the manufacture of biomaterials and drug delivery dosage
 forms for clinical trials and the market. The company formulates
 long-acting products for its clients' active pharmaceutical ingredients.
 These active pharmaceutical ingredients include peptides, proteins, small
 molecules, nucleic acids, and other biological macromolecules. In addition
 to microsphere and implants, Brookwood provides drug delivery technology
 with solid-lipid nanoparticles, liposomes, and hydrophobic drug salts.
 Brookwood Pharmaceuticals holds more than 20 patents in drug delivery and
 is adding new process and formulation patents to its proprietary technology
 portfolio. For further information, see
     About Genzyme Pharmaceuticals
     Genzyme Pharmaceuticals works with pharmaceutical and biotechnology
 companies in the development and manufacture of specialty pharmaceutical
 materials and drug delivery technologies. Its technologies, products and
 services are focused primarily in the peptide, amino acid derivative, lipid
 and drug delivery markets. Genzyme Pharmaceuticals offers two novel drug
 delivery technologies. LipoBridge(R) is an innovative technology
 specifically designed to facilitate transport of drug compounds across the
 blood brain barrier (BBB) and into the Central Nervous System (CNS).
 LipoMask(R) is designed to increase the circulation half life of drug
 substances in blood. For further information, see
     About Genzyme
     One of the world's leading biotechnology companies, Genzyme is
 dedicated to making a major positive impact on the lives of people with
 serious diseases. This year marks the 25th anniversary of Genzyme's
 founding. Since 1981, the company has grown from a small start-up to a
 diversified enterprise with more than 8,000 employees in locations spanning
 the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by
 FORTUNE as one of the "100 Best Companies to Work For" in the United
     With many established products and services helping patients in more
 than 80 countries, Genzyme is a leader in the effort to develop and apply
 the most advanced technologies in the life sciences. The company's products
 and services are focused on rare inherited disorders, kidney disease,
 orthopedics, cancer, transplant and immune diseases, and diagnostic
 testing. Genzyme's commitment to innovation continues today with a
 substantial development program focused on these fields, as well as heart
 disease and other areas of unmet medical need. For further information, see
     This press release contains forward-looking statements, including
 without limitation statements about the anticipated results of the
 Brookwood-Genzyme collaboration; the potential development of new
 technologies and products; and the potential benefits to customers. These
 statements are subject to risks and uncertainties that could cause actual
 results to differ materially from those projected in these forward-looking
 statements. These risks and uncertainties include, among others: Genzyme's
 ability to develop drug delivery solutions and combine its materials and
 technologies with Brookwood's materials and technologies; Genzyme's ability
 to market and sell its technologies and products to customers; the actual
 results of the development work performed during the collaboration and the
 analysis of such data; and the risks and uncertainties described in reports
 filed by Genzyme with the Securities and Exchange Commission under the
 Securities Exchange Act of 1934, as amended, including without limitation
 the information under the heading "Factors Affecting Future Operating
 Results" in the Management's Discussion and Analysis of Financial Condition
 and Results of Operations section of the Genzyme Annual Report on Form 10-K
 for the period ended December 31, 2005. Genzyme cautions investors not to
 place undue reliance on the forward-looking statements contained in this
 press release. These statements speak only as of the date of this press
 release, and Genzyme undertakes no obligation to update or revise these
     Genzyme Pharmaceuticals' press releases and other company information
 are available at
     Contact information:
     David Wyatt, Senior Director          Thomas R. Tice, Executive VP
     Commercial Development                & Chief Scientific Officer
     Genzyme Pharmaceuticals               Brookwood Pharmaceuticals
     tel: (800) 868-8208                   tel: (205) 917-2200
          or (617) 374-7248
     e-mail:   e-mail:

SOURCE Brookwood Pharmaceuticals